In-vitro activity of FK 037 (Cefoselis), a novel 4th generation Cephalosporin, compared to Cefepime and Cefpirome on nosocomial staphylococci and gram-negative isolates☆
- 20 March 2000
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 36 (3), 185-191
- https://doi.org/10.1016/s0732-8893(99)00131-5
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae Isolates from Clinical Samples and Activities of Cephalosporins and CarbapenemsAntimicrobial Agents and Chemotherapy, 1998
- Comparison of the in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species.Journal of Antimicrobial Chemotherapy, 1997
- Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivoJournal of Antimicrobial Chemotherapy, 1997
- In vitro Time-Kill Curves of Cefepime and Cef pirome Combined with Amikacin, Gentamicin or Ciprofloxacin against Klebsiella pneumoniae Producing Extended-Spectrum Beta-LactamaseChemotherapy, 1997
- In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 1996
- In vivo antibacterial activity of FK307, a novel parenteral broad-spectrum cephalosporin.The Journal of Antibiotics, 1993
- In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.The Journal of Antibiotics, 1993